Aim: The objective of the research was to ascertain the incidence rate of psychiatric disorders among individuals diagnosed with chronic plaque psoriasis. Materials and Methods: The study incorporated an equivalent number of healthy controls and 50 patients diagnosed with psoriasis. A 61-item survey questionnaire called Skindex and the Self-Reporting Questionnaire 24 (SRQ24) were utilized to evaluate psychiatric morbidity in both groups. Results :Psychiatric morbidity as measured by the SRQ was 63.1% in the study group and 19.5% in the control group. The observed difference exhibited statistical significance (P < 0.001). The association between psychiatric morbidity and guttate psoriasis was the strongest (100%), followed by plaque type (65.6%) and palmoplantar type (40.8%). Anger constituted the prevailing psychiatric morbidity among individuals diagnosed with psoriasis, as reported by Skindex, with a prevalence of 60%. Discomfort (54%), social dysfunction (54%), cognitive decline (52%), embarrassment (52%), physical restriction (50%), anxiety (50%), and depression (46%) followed suit. All parameters of the Skindex-observed psychiatric morbidity difference between the case and control groups were found to be statistically significant (P < 0.0001). Conclusion: There is considerable psychiatric morbidity associated with psoriasis, and the magnitude of this co-morbidity surpasses previous estimates.